Invokana Lawyer

Invokana Lawsuit Timeline Chronology of Invokana's Product Development and Problems

  • December 10, 2009: Invokana CANVAS Study Begins
    • Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, begins the CANagliflozin cardioVascular Assessment Study (CANVAS) to research the cardiovascular risk for major adverse cardiac events of patients taking Invokana.
  • May 1, 2010: Janssen’s Phase III Clinical Trials for Invokana Conducted
    • Janssen conducts a global study of over 10,000 participants takign Invokana to test the drug’s safety and efficacy.
  • July 1, 2011: Janssen’s Phase II Clinical Trials for Invokana Conducted
    • A study of 279 patients with type 2 diabetes is conducted to test the effects of Invokana.
  • May 31, 2012: Janssen Officially Submits New Drug Application to FDA for Invokana
    • After acquiring the global licensing rights to Invokana from Mitsubishi Tanabe Pharma Corporation, Janssen submitted its New Drug Application to the Food and Administration.
  • June 8, 2012: Janssen offers Invokana research data to diabetes conference
    • The American Diabetes Association’s Scientific Sessions the largest annual research and clinical meeting on diabetes. Sessions focus on the latest information in the areas of basic and clinical research of diabetes and on the application of this information to clinical practice.
  • January 11, 2013: FDA Endocrinologic and Metabolic Drugs Advisory Committee recommends approval of Invokana
    • The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee votes 10 to 5 recommending the Invokana be approved for sale and marketing in the United States.
  • March 29, 2013: FDA Approves Invokana
    • Invokana becomes the first sodium-glucose cotransporter 2 (SGLT2) inhibitors approved to treat type 2 diabetes in the country.
  • April 14, 2014: Invokana Sales at $94 Million for First Quarter of 2014
    • The first available quarterly sales show Invokana generating just under $100 million in sales world wide.
  • July 14, 2014: Invokana Sales Reported at $117 Million for Second Quarter of 2014
    • Invokana continues strong quarter-over-quarter sales growth.
  • October 14, 2014: Invokana Sales Estimated to be over $150 million in Third Quarter of 2014
    • On the heels of strong Invokana sales, Johnson & Johnson’s quarterly sales rose 59 percent to $4.75 billion for the third quarter of 2014.
  • January 20, 2015: Invokana Sales Rise Again in Fourth Quarter of 2014 to $201 Million
    • Invokana continues to be one of Johnson & Johnson’s fastest growing prescription drugs with sales of over $200 million worldwide.
  • April 14, 2015: First Quarter Invokana Sales in 2015 Skyrocket to $278 Million
    • Ivokana sales almost triple compare to figures from the previous year’s first quarter.
  • May 15, 2015: FDA Issues Drug Safety Communication for Invokana
    • The Food and Drug Administration warns Invokana users taking the type 2 diabetes medication could result in ketoacidosis.
  • June 12, 2015: European Medicines Agency Initiates Review of Invokana
    • At the request of the European Commision, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) began an evaluation of the safety of Invokana and other SGLT2 inhibitors.
  • June 22, 2015: Health Canada Begins Starts Invokana Review
    • Following the actions of the FDA and EMA, Health Canada initiated its own review of Invokana after reports of Invokana and other SGLT2 inhibitor users being hospitalized with ketoacidosis.
  • June 23, 2015: The Cochran Firm, D.C. Begins Investigating Invokana
    • After receiving multiple reports from Invokana users concerned their injuries may be the result of side effects from taking the drug, The Cochran Firm, D.C. launches its investigation into the safety of Invokana.
  • July 14, 2015: Second Quarter Invokana Sales in 2015 Soar to $318 Million
    • Based on these sales figures, Invokana is expected to do over $1.5 billion in sales in 2015.